文献速递慢性肾脏病血液净化与透析

尿毒症与甲状旁腺激素对骨蛋白及基因表达的差异化影响

Uremia and parathyroid hormone have distinct effects on bone protein and gene expression.
PubMed 文献 · Kidney Int · 2026-01-20

该研究比较76例血液透析患者与33例对照者的骨组织学及骨细胞基因/蛋白表达,发现CKD与炎症信号增强、细胞死亡增加、成骨分化受损及骨量减少相关;PTH升高可减轻上述改变,但同时上调纤维化、基质沉积和骨重建相关基因,导致皮质孔隙率增加。结论提示PTH对骨质量具有保护与损害的双重效应,联合合成代谢药物与较低PTH水平或可改善CKD骨质量。

要点

  • CKD透析患者骨组织存在炎症信号增强、细胞死亡增加和成骨分化受损。
  • PTH升高可减轻上述骨损伤,但增加纤维化及骨重建相关基因表达。
  • PTH升高与皮质孔隙率增加相关,提示对骨质量有双重影响。

核心结论

  • CKD诱导骨组织炎症和细胞死亡,而PTH升高对骨组织质量和强度呈现保护与损害双重效应。
  • 联合合成代谢药物与相对较低PTH水平可能是改善CKD骨质量的潜在策略,尚需未来研究验证。

研究设计与样本

  • 研究纳入76例接受血液透析的患者,并与33例对照个体进行比较。
  • 采用骨组织学检查及骨细胞基因和蛋白表达分析,包括骨组织bulk RNAseq。

主要发现

  • CKD与炎症信号增强、细胞死亡增加、成骨细胞分化受损及骨量减少相关,与骨细胞计数低和凋亡增加一致。
  • PTH水平升高的患者上述改变减轻,但纤维化、基质沉积和骨重建相关基因表达增加,导致皮质孔隙率增加。

临床怎么用

  • 当前以维持PTH相对充足水平来保留正常骨转换的治疗策略下,患者仍发生骨折,需关注PTH对骨质量的双重影响。
  • 可考虑将合成代谢药物与相对较低PTH水平联合作为改善CKD骨质量的潜在方向。

局限性

  • PTH联合合成代谢药物改善骨质量的假设尚需未来研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Chronic kidney disease (CKD)-associated osteoporosis is highly prevalent and increases the risk of fractures. Current therapy aims to preserve normal bone turnover, by maintaining parathyroid hormone (PTH) at relatively adequate levels. However, these patients continue to experience fractures. METHODS: To assess potential adverse effects of PTH on bone, we examined bone histology and osteocytic gene and protein expression in 76 patients receiving hemodialysis compared to that of 33 control individuals. RESULTS: Using bulk bone tissue RNAseq, we observed that CKD is associated with enhanced inflammatory signaling, increased cell death, impaired osteoblastic differentiation, and reduced bone mass, consistent with low osteocyte count and increased apoptosis. Patients with elevated PTH levels showed an attenuation of these alterations, but exhibited increased expression of genes related to fibrosis, matrix apposition, and bone remodeling, leading to increased cortical porosity. CONCLUSIONS: CKD induces inflammation and cell death in bone. However, elevated PTH levels exhibited dual effects that were both protective and detrimental to bone tissue quality and strength. Our findings suggest that combining anabolic agents with relatively low PTH levels may be a potential approach to improve bone quality in CKD. This hypothesis warrants further investigation in future studies.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Wagner CS, Elias RM, Nickolas TL, et al. Uremia and parathyroid hormone have distinct effects on bone protein and gene expression. Kidney Int. 2026. PMID: 41571099. doi:10.1016/j.kint.2025.12.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。